This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Akhtar, S. Articles by Petrie, J. R Search for Related Content Social Bookmarking                         What's this?

Review: Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk

Division of Medicine and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK

Ciara Kelly

Department of Psychological Medicine, Gartnavel Royal Hospital, University of Glasgow, UK

Andrew Gallagher

Diabetes Centre, Macquaker Building, Victoria Infirmary, Glasgow, UK

John R Petrie

Division of Medicine and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK, johnp{at}memo.dundee.ac.uk

With widespread use of `atypical' antipsychotics for the treatment of psychiatric disorders, attention has focused on their association with obesity, diabetes and risk factors for cardiovascular disease. People with schizophrenia are more likely to develop diabetes than the general population, with antipsychotics appearing to add to this risk. The exact mechanism(s) by which antipsychotics cause hyperglycaemia, diabetic ketoacidosis and aggravation of pre-existing diabetes remain uncertain. Plausible mechanisms have been postulated for the promotion of obesity by these agents, with resultant insulin resistance and type 2 diabetes in some patients. Whatever the mechanism, careful consideration of potential risks and benefits is required in prescribing: people with schizophrenia are often exposed to antipsychotic agents in the long term and frequently have co-existing cardiovascular risk factors (smoking, poor diet, physical inactivity, social deprivation). Regular monitoring of body weight, blood glucose and serum lipids may help clinical management.

Key Words: antipsychotics • diabetes • dyslipidaemia • insulin resistance • metabolic syndrome • obesity.

References

• Marder SR, Essock SM, Miller AL et al. The Mount Sinai Conference on the pharmacotherapy of schizophrenia. Schizophrenia Bulletin 2002;28 (1):5-16.[Abstract/Free Full Text]
• Leucht S., Pitschel-Walz G., Abraham D. et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials. Schizophr Res 1999;4(35):51-68.
• Hummer M., Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004;20:189-97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Druss BG, Bradford WD, Rosenheck RA et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psych 2001;58:565-72.[Abstract/Free Full Text]
• Thiesen FM, Geller F., Schafer H. et al. Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatr Res 2001;35:339-45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dinan TG (ed.). Schizophrenia and diabetes 2003: an expert consensus meeting. Br J Psych 2004;184:(suppl 7):S53-S114.[CrossRef][Web of Science]
• Zhang Z-J., Yao Z-J., Liu W. et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br JPsych 2004;184:58-62.[CrossRef]
• Thakore JH, Mann JN, Vlahos I. et al. Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-41.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ryan MCM, Collins P., Thakore JH Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naïve Patients with Schizophrenia. Am J Psychiatry 2003;160:284-9.[Abstract/Free Full Text]
• Dixon L., Weiden P., Delahanty J. et al. Prevalence and correlates of diabetes in national schizophrenia sample. Schizophrenia Bulletin 2000;26:903-12.[Abstract/Free Full Text]
• Lawrence DM, Holman CDJ, Jablensky AV et al. Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. Br J Psychiatry 2003;182:31-6.[Abstract/Free Full Text]
• Davidson S., Judd F., Jolley D. et al. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001;35:196-202.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Geddes J., Freemantle N., Harrison P. et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.[Abstract/Free Full Text]
• Klett EM, Caffey EM Weight changes during treatment with phenothiazine derivatives. J Neuropsychiatry 1960;2:102-08.[Medline] [Order article via Infotrieve]
• Allison DB, Casey DE Antipsychotic-induced weight gain: a review of the literature. J Clin Psych 2001:62(suppl 7):22-31.
• Taylor DM, McAskill R. Atypical antipsychotic agents and weight gain - a systematic review. Acta Psychiatrica Scand 2000;101:416-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Safety 2001;24(1):59-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Volavka J., Czobor P., Sheitman B. et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62.[Abstract/Free Full Text]
• Czobor P., Volavka J., Sheitman B. et al. Antipsychotic - induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22:244-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wetterling T., MuBigbrodt HE Weight Gain: Side effect of atypical neuroleptics? J Clin Psychopharmacol 1999;19:316-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Henderson DC, Cagliero E., Gray C. et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-81.[Abstract/Free Full Text]
• Robinson RG, McHugh PR, Folstein MF Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res 1975;12(1):59-68.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry 2001;46:549-55.[Web of Science][Medline] [Order article via Infotrieve]
• Wang G., Volkow ND, Pappas NR et al. Brain dopamine and obesity. Lancet 2001;357:354.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• McIntyre RS, Mancini DA, Basile VS et al. Antipsychotic-induced weight gain: bipolar disorder and leptin. J Clin Psychopharmacol 2003;23:323-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 2003;23 (1):S21-S26.
• McIntyre RS, McCann SM, Kennedy SH Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273.[Web of Science][Medline] [Order article via Infotrieve]
• Ellingrod VL, Miller D., Schultz SK et al. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatric Genetics 2002;12(1):55-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Yuan X., Yamada K., Ishiyama-Shigemoto S. et al. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type 2 diabetes. Diabetologia 2000;43:373-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Reynolds GP, Zhang Z., Zhang X. Polymorphism of the promoter region of the serotonin 5- HT2C receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003;160:677-9.[Abstract/Free Full Text]
• Littrell KH, Petty RG, Hilligoss NM et al. Weight loss associated with olanzapine treatment. J Clin Psychopharmacol 2002;22:436-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• O'Keefe CD, Noordsy DL, Liss TB et al. Reversal of antipsychotic-associated weight gain. J Clin Psychiatry 2003;64:907-12.[Web of Science][Medline] [Order article via Infotrieve]
• Shiloah E., Witz S., Abramovitch Y. et al. Effect of acute psychotic stress in nondiabetic subjects on [beta]-cell function and insulin sensitivity. Diabetes Care 2003;26:1462-7.[Abstract/Free Full Text]
• Koller E., Schnieder B., Bennett K. et al. Clozapine-associated diabetes. Am J Medicine 2001;111:716-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Koro CE, Fedder DO, L'Italien GJ et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243-5.[Abstract/Free Full Text]
• Lund BC, Perry P., Brooks JM et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidaemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001;58:1172-6.[Abstract/Free Full Text]
• Sernyak MJ, Leslie DL, Alarcon RD et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.[Abstract/Free Full Text]
• Buse JB Metabolic side effects of antipsychotics: focus on hyperglycaemia and diabetes. J Clin Psychiatry 2002;63:37-41.[Web of Science][Medline] [Order article via Infotrieve]
• Yazicki KM, Erbas T., Yazici AH The effect of Clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 1998;106:475-7.[Web of Science][Medline] [Order article via Infotrieve]
• Sowell M., Mukhopadhyay N., Cavazzoni P. et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinaemic, euglycaemic clamp. J Clin Endocrinol Metab 2003;88:5875-80.[Abstract/Free Full Text]
• Newcomer JW, Haupt DW, Melson AK et al. Insulin resistance measured with euglycaemic clamps during antipsychotic treatment in schizophrenia. Biol Psychiatry 2002;51:1S-198S (abstract only).[CrossRef][Medline] [Order article via Infotrieve]
• Lindenmayer J., Czobor P., Volavka J. et al. Changes in glucose and cholesterol levels in patients with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6.[Abstract/Free Full Text]
• Haupt DW, Melson AK, Schweiger JA et al. Decreased MINMOD insulin sensitivity during antipsychotic treatment of schizophrenia. Biol Psychiatry 2002;51:1S-198S (abstract only).[CrossRef][Medline] [Order article via Infotrieve]
• Ardizzone TD, Bradley RJ, Freeman AM et al. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Research 2001;923: 82-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Shand BI, Scott RS, Elder PA et al. Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes Obes Metab 2003;5:349-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Vasseur F., Lepretre F.,Lacquemant C. et al. The genetics of adiponectin. Curr Diab Rep 2003;3:151-8.[Medline] [Order article via Infotrieve]
• Koller EA, Cross JT, Doraiswamy PM et al. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 2003;23:1123-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gupta S., Steinmeyer C., Bradford F. et al. Hyperglycaemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther 2003;10:348-55.[CrossRef][Medline] [Order article via Infotrieve]
• Ghaeli P., Dufresne RL Serum triglyceride levels in patients treated with Clozapine. Am J Health Syst Pharm 1996;53:2079-81.[Web of Science][Medline] [Order article via Infotrieve]
• Bouchard RH, Demers M., Simoneau I. et al. Atypical antipsychotics and Cardiovascular Risk in Schizophrenic patients. J Clin Psychopharmacol 2001;21:110-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (final report). Circulation 2002;106:3143-421.[Free Full Text]
• Stark C., MacLeod M., Hall D. et al. Mortality after discharge from long-term psychiatric care in Scotland 1977-1994: a retrospective cohort study. BMC Public Health 2003;3(1):30.[CrossRef][Medline] [Order article via Infotrieve]
• Case CC, Jones PH, Nelson K. et al. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab 2002;4:407-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 5, 303-309 (2004)
DOI: 10.1177/14746514040040050301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Akhtar, S. Articles by Petrie, J. R Search for Related Content Social Bookmarking                         What's this?